Rima A. DeFatta, MD; Johnathan B. Sataloff; Grace E. Klaris; Robert T. Sataloff, MD, DMA, FACS A 59-year-old man, a business development consultant, presented with progressive dysphonia. His vocal problems had had a negative impact on his ability to communicate with his clients, and as a result, he was losing income. His symptoms included breathiness, voice breaks, decreased projection, vocal fatigue, and a globus sensation. His voice handicap index (VHI) at presentation was 84.
Flexible and rigid strobovideolaryngoscopy revealed extensive transglottic respiratory papillomatosis (figure, A). The patient was advised that surgical excision would require multiple staged procedures to balance voice preservation with disease control. Conservative excision with cold instruments was accomplished initially, and a small focus of papilloma was left intact along the anterior third of the vibratory margin of the right vocal fold to decrease the risk of web formation. Cidofovir was injected at the base of all lesions.
The patient underwent four microlaryngoscopies approximately 8 weeks apart. Laryngopharyngeal re-flux was treated with a twice-daily proton-pump inhibitor and an H 2 blocker at bedtime. He also underwent voice therapy both pre-and postoperatively. At his most recent follow-up, his vocal fold vibration was only mildly restricted, his glottic closure was complete, and there was no evidence of webbing. There was a 2-mm focus of papilloma along the right vocal process that did not impinge on vocal fold motion or affect glottic closure (figure, B). His VHI improved to 7.
Adults with laryngeal papillomatosis usually present with dysphonia secondary to glottic involvement; in children, on the other hand, the disease is more likely to threaten airway patency. Voice preservation is one of the goals of treatment in adults, but it must be balanced against the burden of disease control. 1, 2 Excessive resection confers little therapeutic advantage because normal-appearing mucosa has been shown to contain human papillomavirus DNA in patients with dormant disease. 3 However, aggressive singlestage procedures can increase the risk of scarring, webbing, and stenosis. It is important to counsel patients regarding the chronic and recurrent nature of this disease and the potential necessity for multiple surgeries to obtain optimal results. The utility of adjunctive therapies (indole-3-carbinol, interferon, photodynamic therapy, cidofovir) in the management of adult recurrent respiratory papillomatosis has not been convincingly supported by the literature. 4 However, their use should be considered in each individual case. It is the practice of the senior author (R.T.S.) to inject intralesional cidofovir routinely (15-mg/ml dilution) if the patient is willing to accept the risks associated with this agent. No adverse effects, including malignant transformation, have been observed in any of our patients after more than 10 years of administering this treatment.
